Orphan Drug Designation Meaning

The US and EU tests differ in three main ways. The US test is about rarity only: a disease affecting less than 200,000 persons in the United States, or one where US sales won't recover the development cost. The EU sets a lower bar of not more than 5 in 10,000 people in the EU, and adds two more tests: the disease must be life-threatening or chronically debilitating, and there must be no satisfactory authorised treatment or the product must offer a significant benefit. In the US, comparing the product with existing therapy happens only at approval, through "clinical superiority" for exclusivity. In the EU, that comparison is already required at designation.

Point	United States (FD&C Act § 526–527; 21 CFR Part 316)	European Union (Regulation (EC) No 141/2000)
Rarity test	"Affects less than 200,000 persons in the United States" [1]	EU prevalence "not more than 5 in 10,000" (EMA)
Alternative economic test	Over 200,000, but "no reasonable expectation" that development costs "will be recovered from sales in the United States" [1]	Marketing unlikely "to generate sufficient returns to justify the investment" (EMA). The Commission's draft notice says this is assessed on "all costs (past and future development costs) and expected revenues" (Commission, PHARM 689, p. 4)
How serious the disease must be	The statute sets no seriousness test; the definition turns on rarity or cost recovery alone [1]	Must be "life-threatening or chronically debilitating" (EMA)
Comparison with existing treatment at designation	The statute sets none; the designation test is that the drug is being investigated for a rare disease [1]	There must be "no satisfactory method" authorised, or the product must give "significant benefit" (EMA). Significant benefit means "a clinically relevant advantage or a major contribution to patient care" (Commission draft, p. 5)
Population counted	Persons in the US, judged "as of the date the request for designation... is made" [1]	EU only; "prevalence of the disease or condition outside the EU has no influence" (Commission draft, p. 4). For diagnostics and preventives such as vaccines, the count is the population treated each year (p. 3)
Subsets of a common disease	An "orphan subset" is allowed if properties of the drug make the remaining patients inappropriate candidates (21 CFR 316.3(b), 316.20(b)(6), eCFR)	Patients in the subset need "distinct and unique evaluable characteristic(s)". Biomarker-based subsets are "not acceptable unless it is proved that the product is ineffective in the rest of the population" (Commission draft, p. 4)
Timing of the request	The request "shall be made before" the NDA or BLA is submitted [1]	"At any stage in the development... before the application for marketing authorisation is made" (Article 5(1), as quoted in the Commission draft, p. 9)
Who decides	FDA designates once the criteria are met [1]	COMP gives an opinion by day 90, and the Commission decides "within 30 days" (EMA, applying)
Re-check at approval	The statute has no re-check of designation. Instead, a later "same drug" must show it is "clinically superior" to get exclusivity [2]	COMP re-checks all criteria at the marketing authorisation stage. A product that no longer meets them "must be removed from the register" (Commission draft, pp. 6–7; EMA, MA page)
Exclusivity once approved	7 years for the same drug for the same disease. Exceptions: the holder cannot supply enough, or consents in writing [2]	10 years, plus 2 more with paediatric investigation plan data. It can be cut to 6 years if the criteria are no longer met at the end of year 5. Derogations: consent, insufficient supply, or clinical superiority (EMA pages above)

What this means in practice:

• Prevalent conditions: A condition around the US 200,000 mark can qualify in one region and not the other, depending on how the EU and US counts work out. Each authority applies its own count and its own point in time.
• Indications that already have approved treatments: Getting an EU designation needs a significant-benefit case from day one. The US designation request has no equivalent test. Under the FD&C Act, comparison with existing drugs comes in only when a "same drug" seeks exclusivity ^[2].
• Parallel filings: EMA "encourages parallel applications" with the FDA (EMA). The two dossiers still need region-specific prevalence and, for the EU, a significant-benefit argument.

Approach: I used the Federal Food, Drug, and Cosmetic Act orphan drug sections in the 2023 U.S. Code, FDA's 21 CFR Part 316 on eCFR, EMA's orphan designation and marketing-authorisation pages, and the Commission's 2015 draft interpretative notice on Regulation 141/2000. That notice was circulated to the Pharmaceutical Committee for discussion, so it is not the final adopted text. I couldn't open the text of Regulation (EC) No 141/2000 itself on EUR-Lex, so the EU criteria come from EMA and the Commission.

For EU orphan designations, use EMA's orphan designation register, and I can search it for you here. For US designations, use FDA's Search Orphan Drug Designations and Approvals database at accessdata.fda.gov. Tell me a substance, product name, condition or EU/3 number and I'll look it up in the EU register.

European Union: EMA orphan designation register

• What it lists: Every designation decision, whether positive, withdrawn, expired or negative.
• What each entry gives:
  • active substance
  • intended use
  • EU designation number (format EU/3/YY/NNNN)
  • date of designation or refusal
  • status
  • publication and last-update dates
  • a link to the EMA designation page
• Example: EU/3/26/3256, an mRNA product for cystic fibrosis, is "Positive" with a designation date of 23/06/2026 ^[3]. EU/3/19/2150, for the same condition, shows "Withdrawn", last updated 21/07/2023 ^[4].
• Status matters: A listed designation is not necessarily still active, so check the status field before relying on it.
• Current counts: The register holds 2,199 positive, 982 withdrawn, 88 expired and 2 negative entries.
• Individual pages: Each designation also has its own EMA page, for example EU/3/26/3256.
• Commission's Union Register: Once an orphan medicine has been authorised through the centralised procedure, the Commission's Union Register lists it, as its overview page explains.

United States: FDA database

• What FDA publishes: FDA states it "publishes the generic name and/or trade name of a drug... after we designate a drug as an orphan drug" (FDA, Public Identification of Orphan Drug Designation).
• Search options: You can search by product name, sponsor name, orphan designation and date range. You can show all designations or only approved products.
• Output: Results come as a condensed list, a detailed list or an Excel download (FDA database).

Approach: I searched EMA's orphan designation register and opened FDA's and the European Commission's official pages. The FDA database is not in the datasets I can search, so I can't run US lookups for you here.